166 related articles for article (PubMed ID: 7814888)
1. Complement component C7 is a plasminogen-binding protein.
Reinartz J; Hänsch GM; Kramer MD
J Immunol; 1995 Jan; 154(2):844-50. PubMed ID: 7814888
[TBL] [Abstract][Full Text] [Related]
2. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9.
Tschopp J; Chonn A; Hertig S; French LE
J Immunol; 1993 Aug; 151(4):2159-65. PubMed ID: 8345200
[TBL] [Abstract][Full Text] [Related]
3. Evidence that C5b recognizes and mediates C8 incorporation into the cytolytic complex of complement.
Stewart JL; Kolb WP; Sodetz JM
J Immunol; 1987 Sep; 139(6):1960-4. PubMed ID: 3624872
[TBL] [Abstract][Full Text] [Related]
4. The membrane attack mechanism of complement: photolabeling reveals insertion of terminal proteins into target membrane.
Hu VW; Esser AF; Podack ER; Wisnieski BJ
J Immunol; 1981 Jul; 127(1):380-6. PubMed ID: 7240749
[TBL] [Abstract][Full Text] [Related]
5. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
Hammer CH; Hänsch G; Gresham HD; Shin ML
J Immunol; 1983 Aug; 131(2):892-8. PubMed ID: 6863934
[TBL] [Abstract][Full Text] [Related]
6. The properdin pathway: mechanisms of complement activation and analogies to the classical pathway.
Fearon DT; Austen KF; Ruddy S
Rheumatology; 1975; 6():2-16. PubMed ID: 1105744
[No Abstract] [Full Text] [Related]
7. Deviated lysis: transfer of complement lytic activity to unsensitized cells. I. Generation of the transferable activity on the surface of complement resistant bacteria.
Rother U; Hänsch G; Menzel J; Rother K
Z Immunitatsforsch Exp Klin Immunol; 1974 Nov; 148(2):172-86. PubMed ID: 4283273
[No Abstract] [Full Text] [Related]
8. Studies on the mechanism of bacterial resistance to complement-mediated killing. II. C8 and C9 release C5b67 from the surface of Salmonella minnesota S218 because the terminal complex does not insert into the bacterial outer membrane.
Joiner KA; Hammer CH; Brown EJ; Frank MM
J Exp Med; 1982 Mar; 155(3):809-19. PubMed ID: 6801180
[TBL] [Abstract][Full Text] [Related]
9. Incorporation of human complement C8 into the membrane attack complex is mediated by a binding site located within the C8beta MACPF domain.
Brannen CL; Sodetz JM
Mol Immunol; 2007 Feb; 44(5):960-5. PubMed ID: 16624411
[TBL] [Abstract][Full Text] [Related]
10. Deviated lysis: transfer of complement lytic activity to unsensitized cells. IV. Parital isolation of the activity.
Hänsch G; Rother U; Rother K
Z Immunitatsforsch Immunobiol; 1977 Apr; 153(1):48-59. PubMed ID: 868206
[TBL] [Abstract][Full Text] [Related]
11. Functional properties of the asialo-fifth component of human complement.
Schultz DR; Arnold PI
J Immunol; 1990 Jul; 145(2):655-61. PubMed ID: 2114446
[TBL] [Abstract][Full Text] [Related]
12. The C5b-6 complex: reaction with C7, C8, C9.
Podack ER; Biesecker G; Kolb WP; Müller-Eberhard HJ
J Immunol; 1978 Aug; 121(2):484-90. PubMed ID: 681745
[No Abstract] [Full Text] [Related]
13. Complement-induced ultrastructural membrane lesions: requirement for terminal components.
Packman CH; Rosenfeld SI; Weed RI; Leddy JP
J Immunol; 1976 Nov; 117(5 Pt.2):1883-9. PubMed ID: 993584
[TBL] [Abstract][Full Text] [Related]
14. [Complement activation and biological activities].
Inoue K
Nihon Saikingaku Zasshi; 1976 Jul; 31(4):535-55. PubMed ID: 988219
[No Abstract] [Full Text] [Related]
15. Membrane attack complex of complement: generation of high-affinity phospholipid binding sites by fusion of five hydrophilic plasma proteins.
Podack ER; Biesecker G; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1979 Feb; 76(2):897-901. PubMed ID: 284414
[TBL] [Abstract][Full Text] [Related]
16. Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell-bound C3b or A2C, and species preferences of target cell.
Hänsch GM; Hammer CH; Mayer MM; Shin ML
J Immunol; 1981 Sep; 127(3):999-1002. PubMed ID: 6911149
[TBL] [Abstract][Full Text] [Related]
17. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
18. Proteolysis of the C5b-7 complex: cleavage of the C5b and C6 subunits and its effect on the interaction of the complex with phospholipid bilayers.
Yamamoto KI
J Immunol; 1980 Oct; 125(4):1745-50. PubMed ID: 6997387
[TBL] [Abstract][Full Text] [Related]
19. [Immunoenzyme determination of the C5b-9 complex of the complement system].
Rus H; Niculescu F; Cristea A; Vlaicu R
Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1986; 31(1):35-40. PubMed ID: 3738363
[No Abstract] [Full Text] [Related]
20. Membrane attack by complement.
Podack ER; Tschopp J
Mol Immunol; 1984 Jul; 21(7):589-603. PubMed ID: 6379417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
